French pharma giant Servier buys Edgewise muscular dystrophy biz
Sevasemten deal could be worth up to $2.65B
Edgewise has offloaded its muscular-dystrophy business to Servier in a deal that could eventually be worth as much as $2.65 billion.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Innosphere’s 2026 Life Sciences Incubator will feature a cohort of 38 startups from nine states…
-
Foresight Diagnostics Inc., a Boulder-based cancer diagnostics company that specialized in the development of ultra-sensitive…
-
Enveda Biosciences was recently cleared to begin clinical trials of its drug candidate for the…
-
VitriVax Inc., a Boulder-based vaccine-formulation technology company, has raised $17.25 million in Series B financing.
